The 340B Drug Pricing Program, which provides drug discounts to eligible health providers, continues to face several threats. Although the program was originally created in 1992 to help health providers stretch “federal scarce resources,” critics argue that the program lacks transparency and doesn’t help patients. This has resulted in several media articles targeting 340B hospitals. Additionally, the COVID-19 pandemic has inadvertently jeopardized the eligibility of 340B hospitals, with many already being terminated from the program. Keep reading for the latest updates on 340B. Read More >>>

View PDF